Shareholder Activism As Public Venture Capital? In Some Cases, It’s Icahn’s Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
We never meant to sell ImClone right away, and we don’t intend to flip Biogen Idec if we win the proxy fight, Icahn director says.